{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:59:05Z","timestamp":1792803545753,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jaad.2019.01.035","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T10:48:52Z","timestamp":1548758932000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study"],"prefix":"10.1016","volume":"88","author":[{"given":"Hsien-Yi","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaline Chung-yee","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nien-Feng","family":"Chang Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ju","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Shun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Huei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2019.01.035_bib1","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaad.2019.01.035_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.01.035_bib3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.dsi.2012.08.002","article-title":"T helper type 17 in psoriasis: from basic immunology to clinical practice","volume":"30","author":"Chiu","year":"2012","journal-title":"Dermatologica Sinica"},{"key":"10.1016\/j.jaad.2019.01.035_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2340\/00015555-2989","article-title":"Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: a multicentric prospective cohort study","volume":"98","author":"Chiu","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2019.01.035_bib5","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib6","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/bjd.12461","article-title":"The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C","volume":"169","author":"Chiu","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2019.01.035_bib8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1759720X17720366","article-title":"Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations","volume":"9","author":"Ajeganova","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jaad.2019.01.035_bib9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2019.01.035_bib10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2015.12.017","article-title":"Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])","volume":"74","author":"Strober","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib12","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2019.01.035_bib13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.01.035_bib14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2019.01.035_bib15","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5021\/ad.2016.28.2.222","article-title":"The MARCOPOLO Study of ustekinumab utilization and efficacy in a real-world setting: treatment of patients with plaque psoriasis in Asia-Pacific countries","volume":"28","author":"Youn","year":"2016","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.dsi.2014.09.005","article-title":"Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers","volume":"33","author":"Wang","year":"2015","journal-title":"Dermatologica Sinica"},{"key":"10.1016\/j.jaad.2019.01.035_bib17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: a retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.dsi.2012.09.001","article-title":"Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: an open-label, retrospective, observational study in Taiwan","volume":"31","author":"Wu","year":"2013","journal-title":"Dermatologica Sinica"},{"key":"10.1016\/j.jaad.2019.01.035_bib19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2340\/00015555-2069","article-title":"Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in chinese patients with psoriasis","volume":"95","author":"Chiu","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2019.01.035_bib20","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-4632.2011.05273.x","article-title":"Etanercept use for psoriasis in Taiwan: a case series study","volume":"52","author":"Chiu","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.dsi.2018.06.001","article-title":"Psoriasis in Taiwan: from epidemiology to new treatments","volume":"36","author":"Chiu","year":"2018","journal-title":"Dermatologica Sinica"},{"key":"10.1016\/j.jaad.2019.01.035_bib22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/247553031016a00205","article-title":"How long does the benefit of biologics last? An update on time to relapse and potential for rebound of biologic agents for psoriasis","volume":"16","author":"Kamaria","year":"2010","journal-title":"Psoriasis Forum"},{"key":"10.1016\/j.jaad.2019.01.035_bib23","first-page":"624","article-title":"Remittive effects of intramuscular alefacept in psoriasis","volume":"2","author":"Gordon","year":"2003","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib25","article-title":"Durability of treatment response in patients with moderate to severe psoriasis following withdrawal from or a dose reduction in adalimumab therapy","volume":"52","author":"Blum","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/09546630500472838","article-title":"Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy","volume":"17","author":"Gordon","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2019.01.035_bib27","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jaad.2005.10.029","article-title":"Relapse, rebound, and psoriasis adverse events: an advisory group report","volume":"54","author":"Carey","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjd.12070","article-title":"Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study","volume":"168","author":"Rich","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2019.01.035_bib31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib32","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1111\/bjd.13573","article-title":"Combining biologics with methotrexate in psoriasis: a systematic review","volume":"172","author":"van Bezooijen","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib33","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/apt.14016","article-title":"Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn\u2019s disease: real world experience from a multicentre cohort","volume":"45","author":"Ma","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jaad.2019.01.035_bib34","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/MIB.0000000000001074","article-title":"Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn\u2019s disease: real-world experience from a multicenter cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2019.01.035_bib35","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR)","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2019.01.035_bib36","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamadermatol.2018.0183","article-title":"Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR","volume":"154","author":"Mason","year":"2018","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219301422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219301422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:04:33Z","timestamp":1759273473000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219301422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0190962219301422"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.01.035","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of time to relapse following ustekinumab withdrawal in patients with psoriasis who had responded to therapy: An 8-year multicenter study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.01.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}